TNF and rheumatoid arthritis: Tumor necrosis factor inhibitors (TNFis) are the most widely used class of bDMARDs, with five TNFis, etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol, currently approved for the treatment of RA.